

MICROBA™

Transforming health through the human microbiome

Bell Potter Healthcare Conference 2022

November 2022 | *Authorised for release by the CEO & Chairman*

Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs. This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.

Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.


Financial data – All dollar values in Australian dollars (A\$ or \$) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

Microba's Commercial Model

Global testing services build a proprietary databank driving transformative novel therapies



Company Snapshot



Continuous YoY revenue growth over 5 years of operations



Partnerships with market leaders incl. **SYNLAB** (GR:SYAB), **Illumina** (NASDAQ: ILMN), **Genova Diagnostics**, and **G42**



Large, unique, proprietary microbiome databank



3 key therapeutic programs with lead IBD drug candidate **progressing to Phase 1 trial**



World-leading technology in the emerging **US\$4.89 billion** microbiome sector¹



Globally **leading microbiome expertise** complemented by drug discovery experts including Prof. Ian Frazer

Microbiome Services

Driving global revenues
and data growth

Testing Services - Recent Milestones



USA OPERATIONS COMMENCED

Distribution partnership to open US Healthcare market commenced



GCC OPERATIONS COMMENCED

Distribution partnership to open Middle East market commenced



NEW PRODUCT LAUNCHED

Next generation healthcare product launched to health professionals in beta



PARTNERSHIP SIGNED & COMMENCED


Partnership signed to deliver a world-first personalised consumer health service

Expanding network of global distribution partners

Distribution agreements executed with global market leaders to distribute microbiome testing solutions powered by Microba's world leading Analysis Platform technology.

						
 <p>AU & NZ</p> <ul style="list-style-type: none"> Metagenics is a leader in functional nutrition Large allied health clinician customer base In 2019, the Company finalised a distribution partnership for AU & NZ 	 <p>Europe</p> <ul style="list-style-type: none"> Europe's largest pathology company Presence in over 40 countries Manage 500m tests a year for 10m patients Expansion across key countries in Europe are ongoing 	 <p>US</p> <ul style="list-style-type: none"> Leading GI pathology company >10,000 purchasing clinicians In Dec 2021 the Company signed a distribution partnership for the US healthcare market In June 2022 operations commenced 	 <p>Middle East</p> <ul style="list-style-type: none"> Leading health-tech company Harnessing data and advanced technologies for personalised care In Feb 2022 the Company signed a distribution partnership for the GCC region In June 2022 operations commenced 	 <p>AU</p> <ul style="list-style-type: none"> Fast growth innovative consumer healthcare company backed by nib In May 2022 the Company signed a partnership to deliver a world-first personalised consumer health service 	<p>+</p> <p>New partner</p>	<p>+</p> <p>New partner</p>
<p>Launched Mid 2019</p>	<p>Launched Mid 2021</p>	<p>Launched Mid 2022</p>	<p>Launched Mid 2022</p>	<p>Launched Q3 2022</p>		

Global distribution expansion driving growth post COVID



>20
Leads

10
Qualified opportunities


18
Potential new countries

4
Potential new US distributors

Microbiome Therapeutics

Developing novel monoclonal
microbial cell therapies

Repeatable, scalable, data-driven platform **discovering novel monoclonal microbial cell therapies**



Proprietary microbiome databank driving **multiple therapeutic opportunities through a capital light platform**

Therapeutic programs **addressing large unmet clinical needs**

Inflammatory Bowel Disease

PROGRESSING TO PHASE I



Lead candidate MAP 315 successfully scaled up in manufacturing. CRO appointed, all activities progressing for upcoming Phase I clinical trial



Cancer Immunotherapy

PRECLINICAL



Ahead of schedule. Multiple leads progressed into pre-clinical animal models. First results expected February - March 2023.



Autoimmune Diseases

COMMENCED




Commenced with biobank strains delivered to Ginkgo Bioworks, characterisation activities underway analysis through the Ginkgo platform.




Inflammatory Bowel Disease program – MAP 315

Addressing a key gap in existing therapy for UC sufferers


Ulcerative Colitis Addressable Patient Population¹



Ulcerative Colitis Therapeutic Global Market Size²



MAP 315 has the potential to provide **novel, potent therapeutic benefit** to UC patients through addressing a **key gap** in existing care – **epithelial and mucosal healing**



- More than 7 million patients worldwide live with IBD, and the incidence is increasing each year³
- Currently treated with anti-inflammatory and immunomodulatory medication to dampen the disease and control symptoms, with significant side effects
- Existing therapeutics fail to adequately address epithelial and mucosal healing with >50% of patients unable to achieve sustained remission¹, which frequently leads to surgical intervention⁴
- MAP 315 stimulates epithelial and mucosal healing⁵, a key unmet and novel treatment paradigm for patients living with this debilitating disease

¹ <https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf>

² <https://www.nature.com/articles/d41573-021-00194-5>, <https://www.alliedmarketresearch.com/ulcerative-colitis-market>

³ [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(19\)30333-4/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30333-4/fulltext)

⁴ <https://www.karger.com/Article/Fulltext/458006>

⁵ results from preclinical animal models, data on file

The start of a therapeutic revolution



Q4 CY22 /Q1 CY23
anticipated FDA approval
Feecal doner derived enema
drug product




H1 CY23
anticipated FDA approval
Feecal doner derived oral
capsule drug product



FDA APPROVAL WOULD
CLEAR THE PATH TO MARKET
FOR LIVE MICROBIOME DRUGS,
A NEW MODALITY.

First Generation
Feecal Doner Derived



Second Generation
Bacterial Consortia



Next Generation
Single Strain & Small Molecule



IFF (NYSE: IFF) Allergy Treatment Partnership

Discovering novel microbiome treatments for allergies




- International Flavors & Fragrances Inc. (NYSE: IFF), \$29B¹ market cap
- Industry leader in food, beverage, health, biosciences
- Major global probiotics supplier

Microba has entered into an agreement with multinational player, IFF, to discover novel treatments for multiple forms of Allergy.

- Project to discover novel allergy treatments
- Milestones delivered: multiple leads discovered for asthma, allergic rhinitis, food allergy and atopic dermatitis.
- First step in a potential longer-term commercial relationship to develop novel allergy treatments.

Allergy Treatment Market²
Forecast to grow at CAGR of 6.8%



Outlook



Upcoming Milestones for FY23

2022 OCT – DEC	2023 JAN - MAR	2023 APR - JUN
<p>Services New healthcare product full launch</p>		
<p>Services SYNLAB country expansion</p>		
<p>Services New international distribution deals</p>	<p>Services New international distribution deals</p>	
	<p>Therapeutics - IBD MAP315 program Phase 1 HREC Submission</p>	
	<p>Therapeutics - IBD MAP315 program FDA Pre-IND meeting outcome</p>	<p>Services New international distribution deals</p>
	<p>Therapeutics - IO Program Pre-clinical results</p>	<p>Therapeutics - IBD MAP315 program GMP manufacture complete for Ph1</p>
	<p>Therapeutics – Autoimmune Program First <i>in vitro</i> screening results</p>	<p>Therapeutics - IBD MAP315 program HREC Approval for Phase 1 trial</p>
		<p>Therapeutics - IBD MAP315 program Phase 1 trial commencement</p>

Contact



Dr Luke Reid

Chief Executive Officer
luke.reid@microba.com



Pasquale Rombola

Chairman
pasquale.rombola@microba.com

Head Office

Level 10, 324 Queen Street
Brisbane QLD Australia

Laboratory

Princess Alexandra Hospital
Woolloongabba QLD Australia

MICROBA™